Drozitumab Biosimilar - Research Grade

Human

TNFRSF10B

>1mg/ml

IgG1 - lambda3

CHO Cells

Benufutamab Biosimilar - Research Grade (ICH5390), Conatumumab Biosimilar - Research Grade (ICH5445), Lexatumumab Biosimilar - Research Grade (ICH5640), Tigatuzumab Biosimilar - Research Grade (ICH5921), Tilogotamab Biosimilar - Research Grade (ICH5922)

https://www.imgt.org/mAb-DB/

ICH3002

O14763

Blue ice

This product is an unconjugated, non-therapeutic recombinant analog of drozitumab, a fully human IgG1 monoclonal antibody directed against the death receptor DR5 (TNFRSF10B / TRAIL-R2). It is built around the drozitumab binding specificity and supplied for research use only; it is not the clinical drug and is not intended for human or veterinary use. Unlike neutralizing antibodies, drozitumab is an agonistic antibody that clusters DR5 to mimic TRAIL-driven death-receptor signaling, making this analog a useful tool for probing extrinsic apoptosis in tumor and other cell models. Researchers use it as a defined, reproducible reagent for target-engagement and binding assays, apoptosis-induction studies, receptor-clustering and crosslinking experiments, comparator or benchmark controls against other DR5 agonists, and as a building block for ADC or bispecific-format development. It is available at low-endotoxin research grade and ultra-low-endotoxin grades, and in bulk milligram-to-gram quantities to support assay scale-up, screening campaigns, and preclinical model work requiring consistent lot-to-lot material. TNFRSF10B, better known as DR5 (also TRAIL-R2, KILLER, TRICK2), is a type I transmembrane death receptor of the TNF receptor superfamily and one of two signaling receptors for the cytotoxic ligand TRAIL (TNFSF10). Its extracellular region contains cysteine-rich domains that engage TRAIL, while its cytoplasmic death domain nucleates the extrinsic apoptotic pathway. Upon ligand binding or antibody-induced clustering, DR5 recruits the adaptor FADD and pro-caspase-8 to assemble the death-inducing signaling complex (DISC), activating caspase-8 and the downstream executioner caspase cascade. DR5 also contributes to NF-kappa-B activation and participates in endoplasmic-reticulum-stress-induced cell death. Because many tumor cells are sensitive to DR5-triggered apoptosis, DR5 has been a longstanding target for pro-apoptotic cancer therapeutics, and agonistic antibodies against it are widely studied research tools.

Death receptor 5, TNF-related apoptosis-inducing ligand receptor 2, TRAIL receptor 2, TRAIL-R2, Tumor necrosis factor receptor superfamily member 10B, DR5, KILLER, TRICK2, ZTNFR9

This monoclonal antibody was purified using Protein A

Sterile, preservative-free, solution in PBS. BSA and Azide free.

This biosimilar is stable when stored at 2-8°C. For longer term storage (> 3 months) it is recommended to store this antibody at -20°C or -70°C.

Functional Assays

This biosimilar is for research use only (RUO): it is not for diagnostic or therapeutic procedures and cannot be purchased by patients.

Products are for research use only. Not for use in diagnostic or therapeutic procedures.

3-4 weeks

Q: Is the Drozitumab biosimilar available in bulk or gram quantities?

A: Yes — the Drozitumab biosimilar is manufactured in scalable milligram to gram quantities to support high-throughput and heavy-usage laboratories.

Q: Is this research-grade Drozitumab suitable for in vivo studies?

A: Yes, it is a low-endotoxin, in vivo-ready formulation intended for preclinical and in vivo research use only (RUO).

Q: What does the Drozitumab biosimilar target?

A: It is an unconjugated, non-therapeutic analog of Drozitumab that binds TNFRSF10B.